StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report released on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Up 5.0 %
Shares of NASDAQ:AKTX opened at $2.64 on Friday. Akari Therapeutics has a twelve month low of $2.25 and a twelve month high of $10.18. The company has a 50-day moving average price of $2.89 and a two-hundred day moving average price of $3.43.
Hedge Funds Weigh In On Akari Therapeutics
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Omnia Family Wealth LLC boosted its position in Akari Therapeutics by 48.2% during the fourth quarter. Omnia Family Wealth LLC now owns 87,628 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 28,511 shares during the period. Cerity Partners LLC bought a new position in Akari Therapeutics during the second quarter worth about $55,000. Sabby Management LLC boosted its position in Akari Therapeutics by 116.5% during the first quarter. Sabby Management LLC now owns 7,941,867 shares of the biopharmaceutical company’s stock worth $1,443,000 after purchasing an additional 4,273,528 shares during the period. Renaissance Technologies LLC boosted its position in Akari Therapeutics by 411.4% during the first quarter. Renaissance Technologies LLC now owns 283,550 shares of the biopharmaceutical company’s stock worth $52,000 after purchasing an additional 228,100 shares during the period. Finally, LPL Financial LLC bought a new position in Akari Therapeutics during the second quarter worth about $83,000.
About Akari Therapeutics
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.
- Five stocks we like better than Akari Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- Is the dip in Atlassian stock a sneaky buy opportunity?
- Health Care Stocks Explained: Why You Might Want to Invest
- Caterpillar stock hits new highs; time to ring the register?
- Most Volatile Stocks, What Investors Need to Know
- 5 medical stocks growing earnings by triple digits
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.